Effect of pepleomycin in prostatic cancer. A preliminary report.
Six patients with prostatic carcinoma entered this clinical trial using Pepleomycin, an analogue of Bleomycin, administered intramuscularly in a total dose of 120 mg. Two patients had an objective improvement lasting for three months. Also subjective improvement was observed in one patient. The main side effects were gastrointestinal disturbances, dermatologic symptoms and fever. However, pulmonary fibrosis, a well-known complication of Bleomycin therapy, could not be found.
D000135:Acid Phosphatase / Q000097:blood; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D017663:Peplomycin; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D000903:Antibiotics, Antineoplastic; D001761:Bleomycin; D017663:Peplomycin; D000135:Acid Phosphatase